Difference between revisions of "Boots Healthcare International"
| Line 1: | Line 1: | ||
| − | In October 2005 [[Boots]] agreed to sell its over-the-counter medicines business, Boots Healthcare International, which markets brands such as [[Clearasil]], [[Nurofen]], [[Optrex]], [[E45]] and [[Strepsils]], to the Anglo-Dutch household products company [[Reckitt Benckiser]] for £1.936 billion. The disposal was completed on 31 January 2006. | + | In October 2005 [[Boots]] agreed to sell its over-the-counter medicines business, Boots Healthcare International, which markets brands such as [[Clearasil]], [[Nurofen]], [[Optrex]], [[E45]] and [[Strepsils]], to the Anglo-Dutch household products company [[Reckitt Benckiser]] for £1.936 billion. The disposal was completed on 31 January 2006.<ref>Reckitt Benckiser [http://www.reckittbenckiser.com/RBTemplates/MediaLatestNewsItem.aspx?pageid=196 07/10/2005 Acquisition of Boots Healthcare International] Latest News, accessed 1 December 2007</ref> |
| + | |||
| + | ==Notes== | ||
| + | <references/> | ||
Latest revision as of 09:48, 1 December 2007
In October 2005 Boots agreed to sell its over-the-counter medicines business, Boots Healthcare International, which markets brands such as Clearasil, Nurofen, Optrex, E45 and Strepsils, to the Anglo-Dutch household products company Reckitt Benckiser for £1.936 billion. The disposal was completed on 31 January 2006.[1]
Notes
- ↑ Reckitt Benckiser 07/10/2005 Acquisition of Boots Healthcare International Latest News, accessed 1 December 2007
